Fiche centre
Queen Elizabeth University Hospital
Glasgow — United Kingdom
Essais liés6clinical trials
VilleGlasgowlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02861014
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| lorundrostat | Hypertension | Phase 3 | NCT05968430 | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT02861014 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Obecabtagene autoleucel | Lupus | Phase 2 | NCT07053800 | LUMINA — Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | RECRUITING |
| Deep Brain Stimulation (DBS) | Parkinson | À vérifier | NCT02071134 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | RECRUITING |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |